Chai Discovery enters AI collaboration with Eli Lilly

San Francisco, USA-based Chai Discovery, the AI company building a computer-aided design suite for molecules, has announced a collaboration with pharma major Eli Lilly (NYSE: LLY) to accelerate biologics discovery using artificial intelligence.

Under the collaboration, Lilly will deploy Chai’s frontier AI platform to design novel biologic therapeutics for multiple targets. In addition, Chai will develop a purpose-built AI model, exclusively for use by Lilly, trained on large-scale proprietary Lilly data and tailored to Lilly’s discovery workflows. The collaboration follows a period during which a set of Chai’s model designs were evaluated by Lilly.

This comes as Eli Lilly extends TuneLab, its federated learning platform, via a Benchling integration, giving 1,300+ biotechs access to small-molecule and antibody prediction models trained on $1 billion+ in proprietary molecular and safety data, with a parallel Lilly-Revvity setup using Signals Xynthetica to run TuneLab at scale with secure data exchange and anonymized result-sharing.